Search Result

Results for "

lung+adenocarcinoma

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) ADC Payload (2) Adrenergic Receptor (1) Akt (3) Aldehyde Dehydrogenase (ALDH) (1) AMPK (1) Anaplastic lymphoma kinase (ALK) (2) Antibiotic (2) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (16) Arp2/3 Complex (1) Aurora Kinase (1) Autophagy (1) Bacterial (3) Bcl-2 Family (2) Biochemical Assay Reagents (3) c-Met/HGFR (1) Caspase (4) Choline Kinase (1) Cytochrome P450 (1) DNA Alkylator/Crosslinker (1) DNA Methyltransferase (1) DNA/RNA Synthesis (2) Drug Derivative (1) Drug Intermediate (2) Drug Metabolite (1) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (1) EGFR (1) Environmental Pollutants (1) ERK (3) Fungal (1) Galectin (2) Histone Demethylase (1) IFNAR (1) IGF-1R (1) Insulin Receptor (1) JNK (1) MAP4K (1) Melanocortin Receptor (1) Microtubule/Tubulin (2) MMP (3) Molecular Glues (1) mTOR (1) NAMPT (1) NF-κB (1) NO Synthase (1) Oxidative Phosphorylation (1) p38 MAPK (3) Parasite (1) PARP (4) PD-1/PD-L1 (2) PDGFR (1) PDK-1 (1) PERK (1) Phosphodiesterase (PDE) (1) PI3K (1) PKA (1) PROTACs (3) Pyruvate Kinase (1) RAR/RXR (1) Ras (1) Reactive Oxygen Species (ROS) (4) RET (1) ROR (1) SHP2 (1) Sirtuin (1) STAT (3) STING (1) STK33 (1) Toll-like Receptor (TLR) (1) Topoisomerase (4) Transmembrane Glycoprotein (1) Wnt (1)
By Research Areas:	Cancer (56) Cardiovascular Disease (1) Endocrinology (1) Infection (5) Inflammation/Immunology (5) Metabolic Disease (2) Neurological Disease (3)
Oligonucleotides:	CpG ODNs (1)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-114409

GB1107 Maximum Cited Publications 19 Publications Verification	Galectin	Cancer
GB1107 is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with a K_d of 37 nM for human Galectin-3. GB1107 reduces human and mouse lung adenocarcinoma growth and blocks metastasis in the syngeneic model .

HY-146244

Agatolimod 1 Publications Verification ODN 2006; PF-3512676; CpG 7909; ODN 7909	Toll-like Receptor (TLR) Bacterial NO Synthase Apoptosis	Infection Cancer
Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a TLR9 agonist and immunomodulator with an EC₅₀ of 180 nM against human TLR9. Agatolimod activates and upregulates the expression of both TLR9 and TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis .

HY-P3371

Ifinatamab deruxtecan DS-7300a; MABX-9001a; I-DXd	Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis	Cancer
Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects

HY-148819

NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT	ADC Payload Topoisomerase	Cancer
NH2-bicyclopentane-7-MAD-MDCPT (Formula I) is a topoisomerase I (TOP1) inhibitor. NH2-bicyclopentane-7-MAD-MDCPT is applicable to the synthesis of the ADC ABBV-969. NH2-bicyclopentane-7-MAD-MDCPT is used in research on lung adenocarcinoma and melanoma .

HY-124745

KY-05009 1 Publications Verification	MAP4K Wnt Apoptosis	Cancer
KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a K_i of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity .

HY-401424

Cremophor EL-36 Polyoxyethylene(36) Castor Oil; PEG-36 Castor Oil	Environmental Pollutants Biochemical Assay Reagents	Others
Cremophor EL-36 is a non-ionic surfactant, mainly used as a solubilizing carrier for poorly soluble Paclitaxel (HY-B0015). For example, Cremophor EL-36 can enhance the intracellular influx of Etoposide (HY-13629) without affecting drug efflux, and can dose-dependently increase the accumulation of VP-16 in lung adenocarcinoma cells (such as PC-14 and A549), significantly enhancing its cytotoxic effect .

HY-P99048

Sintilimab 1 Publications Verification IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a K_D value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-W1128879

XMU-MP-8 SKPer1	Molecular Glues E1/E2/E3 Enzyme	Cancer
XMU-MP-8 (SKPer1) is a potent molecular glue degrader that targets the oncoprotein SKP2. XMU-MP-8 simultaneously binds to the F-box domain of SKP2 (K_d ≈ 36 μM) and the N-terminal TPR domain of the E3 ligase STUB1 (K_d ≈ 2.5 μM), forming a stable SKP2-SKPer1-STUB1 ternary complex (K_d ≈ 8.9 nM) that induces SKP2 ubiquitination and proteasomal degradation. XMU-MP-8 selectively eliminates SKP2-expressing cancer cells. XMU-MP-8 exhibits substantial tumour suppression with good safety profiles in vivo. XMU-MP-8 can be used for cancer research, such as non-small cell lung adenocarcinoma (NSCLC) and prostatic adenocarcinoma .

HY-Y0030

3-Hydroxypicolinic acid 3-hydroxypyridine-2-carboxylic acid	Biochemical Assay Reagents Drug Intermediate	Infection Cancer
3-Hydroxypicolinic acid is a heterocyclic carboxylic acid ligand and cytotoxin, with a MIC₉₀ of >25 μg/mL against Mycobacterium tuberculosis H37Rv. 3-Hydroxypicolinic acid inhibits the growth of cancer cells and normal fibroblasts. 3-Hydroxypicolinic acid is applicable to research related to chronic myeloid leukemia, human lung adenocarcinoma, and tuberculosis .

HY-115579

MALAT1-IN-1 3 Publications Verification	DNA/RNA Synthesis	Cancer
MALAT1-IN-1 (compounds 5) is a potent and specific Malat1 (Metastasis-associated lung adenocarcinoma transcript 1) inhibitor. MALAT1-IN-1 modulated Malat1 downstream genes in a dose-dependent manner without affecting expression of nuclear enriched abundant transcript 1 (Neat1) .

HY-148819A

NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT hydrochloride	ADC Payload Topoisomerase	Cancer
NH2-bicyclopentane-7-MAD-MDCPT hydrochloride (Formula I) is a topoisomerase I (TOP1) inhibitor. NH2-bicyclopentane-7-MAD-MDCPT hydrochloride is applicable to the synthesis of the ADC ABBV-969. NH2-bicyclopentane-7-MAD-MDCPT hydrochloride is used in research on lung adenocarcinoma and melanoma .

HY-139434

JMJD6-IN-1	Histone Demethylase	Cancer
JMJD6-IN-1 is a JMJD6 inhibitor, with an inhibition rate of 82% at 10 μM. JMJD6-IN-1 inhibits MCF-7 and HCC4006 cell proliferation with IC₅₀ values of 19.2 μM and 25.2 μM. JMJD6-IN-1 inhibits JMJD6 demethylase activity. JMJD6-IN-1 can be used for the research of lung adenocarcinoma, prostate cancer, breast cancer, pancreatic cancer, colon cancer, oral squamous cell carcinoma, and glioblastoma .

HY-13495

ML281 2 Publications Verification	STK33 PKA Aurora Kinase Bcl-2 Family Apoptosis	Metabolic Disease Cancer
ML281 is a highly selective inhibitor of serine/threonine kinase 33 (STK33) with an IC₅₀ value of 14 nM. ML281 shows 700-fold selectivity over PKA and 550-fold over AurB. ML281 exerts core mechanism by inhibiting STK33: in small cell lung cancer, ML281 downregulates RPS6/BAD signaling phosphorylation, induces apoptosis, and suppresses proliferation, invasion . ML281 reduces STK33-mediated 4-hydroxyphenylpyruvate dioxygenase (HPD) phosphorylation in tyrosinemia . ML281 is suitable for research on STK33 function, KRAS mutation-related cancers (pancreatic cancer, colon cancer, lung adenocarcinoma, etc.), small cell lung cancer, and tyrosinemia-related damage

HY-N3225

Myricanol	NAMPT Sirtuin Microtubule/Tubulin Apoptosis Autophagy PDGFR NF-κB AMPK	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Myricanol is a diarylheptanoid and a Nampt activator. Myricanol exerts anti-inflammatory effects and alleviates glucocorticoid-induced muscle atrophy by increasing Sirtuin 1 (SIRT1) and PRDX5 activities while regulating inflammatory factors. Myricanol exhibits growth inhibition and induces apoptosis in human lung adenocarcinoma A549 cells. Myricanol promotes autophagy-mediated clearance of microtubule-associated protein tau to exert neuroprotective effects. Myricanol protects cardiovascular function by inhibiting PDGFRβ and NF-κB signaling pathways. Myricanol activates mitochondrial transcription factor A (TFAM) expression to exert anti-renal fibrosis effects. Myricanol improves insulin resistance through AMPK activation .

HY-114356

BPI-9016M	c-Met/HGFR	Cancer
BPI-9016M is a potent, orally active, and selective dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma .

HY-147328

LCS3	Apoptosis	Cancer
LCS3 is a reversible and uncompetitive glutathione disulfide reductase (GSR) and thioredoxin reductase 1 (TXNRD1) inhibitor (IC₅₀=3.3 µM and 3.8 µM, respectively). LCS3 shows anti-tumor activity, and induces apoptosis. LCS3 can be used in lung adenocarcinoma (LUAD) research .

HY-17663

KMR-206	PARP STAT STING IFNAR	Cancer
KMR-206 is a PARP7 inhibitor with an IC₅₀ of 13.7 nM. KMR-206 relieves AHR-mediated transcriptional repression and enhances CYP1A1 expression in the presence of TCDD. KMR-206 induces the STING-dependent IFN-β signaling pathway and increases the levels of STAT1, pSTAT1 and nuclear PARP7 in cancer cells. KMR-206 reduces the viability of lung adenocarcinoma cells, enhances radiation-induced immunogenic signals, and induces the production of immunogenic signals in glioblastoma cancer stem cells. KMR-206 destabilizes FRA1 to increase IRF1 levels and promotes the IRF3-CBP/p300 interaction. KMR-206 can be used in studies related to lung adenocarcinoma and glioblastoma .

HY-153796

PROTAC Her3 Degrader-8	PROTACs EGFR	Cancer
PROTAC Her3 Degrader-8 (Compound PP2) is a Her3 PROTAC degrader. PROTAC Her3 Degrader-8 promotes the ubiquitination and degradation of Her3. PROTAC Her3 Degrader-8 can be used in the study of lung adenocarcinoma and ovarian cancer (Pink: Her3 ligand (HY-107450); Blue: E3 ligase ligand (HY-170861); Black: linker (HY-Y1760)) .

HY-N8420

Thalifoline	Fungal	Infection Cancer
Thalifoline is an isoquinoline alkaloid. Thalifoline exerts cytotoxic effects on cancer cells. Thalifoline inhibits the growth of Fusarium oxysporum f. sp. lycopersici. Thalifoline can be used in research related to lung adenocarcinoma, colon cancer, oral epidermoid carcinoma, and fungal infections .

HY-165245

SBI-183	Transmembrane Glycoprotein	Cancer
SBI-183 is an orally active inhibitor of QSOX1 (K_d: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo .

HY-147027

PARP-1-IN-2	PARP Caspase Apoptosis	Neurological Disease Inflammation/Immunology Cancer
PARP-1-IN-2 (compound 11g) is a potent PARP1 inhibitor, with an IC₅₀ of 149 nM, and ADME prediction indicates it has high blood-brain barrier permeability. PARP1-IN-2 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549. PARP1-IN-2 can induce A549 cells apoptosis .

HY-16676

7-Epi-docetaxel 4-epi-Docetaxel; 7-Epidocetaxel; 7-Epitaxotere	Drug Metabolite Cytochrome P450	Cancer
7-Epi-docetaxel (4-epi-Docetaxel; 7-Epidocetaxel; 7-Epitaxotere) is the major C7 epimeric impurity/in vivo metabolite of Docetaxel (HY-B0011). 7-Epi-docetaxel acts as a potent allosteric activator of rhCYP1B1. 7-Epi-docetaxel exhibits certain cell line-specific anti-migratory activity . 7-Epi-docetaxel can be used in research related to melanoma and lung adenocarcinoma .

HY-42121

4-Bromo-2-fluoro-1-iodobenzene 4-Bromo-2-fluoroiodobenzene	Biochemical Assay Reagents Drug Intermediate	Cancer
4-Bromo-2-fluoro-1-iodobenzene is an intermediate. 4-Bromo-2-fluoro-1-iodobenzene can be used in the synthesis of Example 33. 4-Bromo-2-fluoro-1-iodobenzene can be used in lung adenocarcinoma research .

HY-P99048A

Sintilimab (Anti-PD-1) IBI308 (Anti-PD-1)	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a K_D value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-N14303

16-Methyloxazolomycin	Antibiotic Bacterial	Infection Cancer
16-Methyloxazolomycin is an antibiotic. 16-Methyloxazolomycin has the effect of resisting bacteria and algae. 16-Methyloxazolomycin against leukemia P388 and human lung adenocarcinoma cells .

HY-N1056

Yunnancoronarin A Zerumbetol	Others	Cancer
Yunnancoronarin A (Zerumbetol) can be isolated from Hedychium forrestii. Yunnancoronarin A is cytotoxic, with IC₅₀ values of 11.08 and 2.19 μM against lung adenocarcinoma cells A549 and leukemia cells K562, respectively .

HY-111320

Chrysomycin B	Bacterial Antibiotic	Cancer
Chrysomycin B is an antibiotic isolated from a strain of Streptomyces. Chrysomycin B causes DNA damage in the human lung adenocarcinoma A549 cell line and inhibits topoisomerase II. Chrysomycin B suppresses the growth of transplantable tumors in mice.

HY-164713

PARP1-IN-31	Others	Others
PARP1-IN-31 (compound 11f) is a phthalazinone-based compound, an anti-lung adenocarcinoma compound with inhibitory activity against PARP-1 (IC₅₀ value of 97 nM), inducing apoptosis and inhibiting cell proliferation in lung cancer cell lines.

HY-153590

PARP-1-IN-4	PARP	Cancer
PARP-1-IN-4 is a PARP-1 inhibitor. PARP-1-IN-4 has inhibitory activity against PARP-1 with IC₅₀ value of 302 μM. PARP-1-IN-4 can be used for the research of lung adenocarcinoma .

HY-147030

PARP1-IN-8	PARP	Cancer
PARP1-IN-8 (compound 11c) is a potent and BBB-penetrated PARP1 inhibitor, with an IC₅₀ of 97 nM. PARP1-IN-8 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549 .

HY-160021

RORγt agonist 4	ROR	Inflammation/Immunology
RORγt agonist 4 (compound 14) is a potent and selective agonist of RORγt. RORγt agonist 4 significantly enhances metabolic stability. RORγt agonist 4 improves the situation of tumor models of mouse B16F10 melanoma and LLC lung adenocarcinoma .

HY-P10010

DB21, Galectin-1 Antagonist	Galectin	Cancer
DB21, Galectin-1 Antagonist is a dibenzofuran conjugated peptidomimetic that acts as an allosteric inhibitor of galectin-1 (GAL1)binding to cell surface glycans. DB21, Galectin-1 Antagonis increases inhibition of angiogenesis and tumour growth in melanoma, lung adenocarcinoma and ovarian cancer models .

HY-111125

AMRI-59	Parasite Reactive Oxygen Species (ROS) Apoptosis	Infection Cancer
AMRI-59 is a potent inhibitor of PrxI used for parasitic infections. AMRI-59 can increase cellular ROS, leading to activation of signaling pathways mediated by mitochondria and apoptosis signal-regulated kinase 1, thereby leading to apoptosis in A549 human lung adenocarcinoma. AMRI-59 exhibits significant antitumor activity without apparent acute toxicity .

HY-105854

Pipoxolan hydrochloride	Apoptosis Reactive Oxygen Species (ROS) JNK p38 MAPK MMP	Cancer
Pipoxolan hydrochloride is an anti-spasmotic agent. Pipoxolan hydrochloride induces Apoptosis, increases intracellular ROS. Pipoxolan hydrochloride down-regulates phosphorylation JNK and p38, and then, MMP-2 and -9. Pipoxolan hydrochloride relieves smooth muscle spasms in the digestive, urinary, and gynecological systems. Pipoxolan hydrochloride also exhibits anticancer activity against leukemia, oral squamous cell carcinoma, and lung adenocarcinoma .

HY-149085A

(E)-XS-060	RAR/RXR	Cancer
(E)-XS-060 is an isomer of XS-060. XS-060 is a RXRα antagonist. XS-060 inhibits pRXRα-PLK1 interaction. XS-060 induces RXRα-dependent mitotic arrest. XS-060 exhibits good antitumor activity against breast cancer, lung adenocarcinoma, and liver cancer .

HY-172881

PKM2-IN-10	Pyruvate Kinase	Cancer
PKM2-IN-10 (Compound 16) is a PKM2 inhibitor. PKM2-IN-10 inhibits the proliferation of A549 and HCC1833 cell lines with IC₅₀ of 3.36 μM and 9.20 μM, respectively. PKM2-IN-10 exhibits antitumor activity in human non-small cell lung cancer (NSCLC) and mouse lung adenocarcinoma models. PKM2-IN-10 can be used in lung cancer research .

HY-151295

Antitumor agent-75	DNA/RNA Synthesis	Cancer
Antitumor agent-75 is a novel potent antitumor agent. Antitumor agent-75 has cytotoxic effects on cancer and normal human cell lines. Antitumor agent-75 shows a highly selective cytotoxic effect against human lung adenocarcinoma (cell line A549) when combined with Antitumor agent-74 (HY-151292), the IC₅₀ value of 2.8 μM. Antitumor agent-75 can be used for the research of cancer .

HY-N6969A

Dicentrine hydrochloride	Adrenergic Receptor	Cancer
Dicentrine hydrochloride is a drug with anti-inflammatory and anti-cancer activity. Dicentrine hydrochloride exerts its effects by enhancing TNF-α-induced apoptosis in A549 lung adenocarcinoma cells. Dicentrine hydrochloride increases caspase-8, -9, -3 and poly(ADP-ribose) polymerase (PARP) activities. Dicentrine hydrochloride inhibits TNF-α-induced invasion and migration of A549 cells. Dicentrine hydrochloride significantly inhibited the TNF-α-activated TAK1, p38, JNK and Akt signaling pathways, and reduced the transcriptional activities of NF-κB and AP-1 .

HY-181020

Deltafluorine	Phosphodiesterase (PDE) p38 MAPK Akt mTOR ERK	Cancer
Deltafluorine is a phosphodiesterase delta (PDEδ) inhibitor with an IC₅₀ of 27 nM, a K_D of 148 nM. Deltafluorine covalently modifies the specific glutamate residue p.E88 in the ligand binding site of PDEδ, interfering with its chaperone function. Deltafluorine inhibits signaling through the MAPK and Akt-mTOR pathway, reduces ERK1/2 expression. Deltafluorine reduces tumor volume in an autochthonous mouse model of Kras-driven lung adenocarcinoma. Deltafluorine can be used for the research of lung adenocarcinoma .

HY-182883

KRASG12C IN-20	Ras	Cancer
KRASG12C IN-20 is an orally potent KRAS ^G12C inhibitor with an EC₅₀ of 3.9 nM. KRASG12C IN-20 covalently modifies KRAS ^G12C in its inactive GDP-bound state and locks it to block oncogenic signal transduction. KRASG12C IN-20 exhibits significant activity in lung adenocarcinoma xenograft models. KRASG12C IN-20 can be used for research related to lung adenocarcinoma .

HY-N17957

Homoisopogon B	Others	Cancer
Homoisopogon B is a homoisoflavane found in the tubers of Ophiopogon japonicus. Homoisopogon B shows cytotoxic activity against cancer cells. Homoisopogon B can be used for the research of cancer, such as human lung adenocarcinoma and human melanoma .

HY-179501

PDK1-IN-5	PDK-1 Reactive Oxygen Species (ROS) Apoptosis Oxidative Phosphorylation	Cancer
PDK1-IN-5 is a selective PDK1 inhibitor. PDK1-IN-5 activaties PDH by diminishing phosphorylation level via PDK1 inhibition. PDK1-IN-5 effectively reverses the Warburg effect and shifts cellular energy metabolism from glycolysis toward oxidative phosphorylation by increased acetyl-CoA, reduced lactate, elevated mitochondrial ROS, and subsequent induction of apoptosis. PDK1-IN-5 robustly inhibits tumor growth in vivo without inducing systemic toxicity. PDK1-IN-5 can be used for lung adenocarcinoma, human non-small cell lung adenocarcinoma and gastric colorectal .

HY-N17684

Abietatriene-3β-ol	Others	Cancer
Abietatriene-3β-ol is an anticancer agent. Abietatriene-3β-ol can be isolated from leaves of Thuja orientalis L. Abietatriene-3β-ol exhibits anticancer activity against non-small cell lung adenocarcinoma, ovarian cancer cells, skin melanoma, and colon cancer .

HY-N11764

β-Santalol	Apoptosis Caspase	Cancer
β-Santalol is a sesquiterpene alcohol with apoptosis (apoptosis)-inducing activity and cytotoxic activity. β-Santalol activates caspase-3, induces nuclear chromatin condensation, and promotes the formation of apoptotic bodies. β-Santalol targets cancer cells. β-Santalol can be used in research related to promyelocytic leukemia, lung adenocarcinoma, and oral squamous cell carcinoma .

HY-153503

ALK-IN-24	Anaplastic lymphoma kinase (ALK) Insulin Receptor	Cancer
ALK-IN-24 is an orally active ALK inhibitor with an IC₅₀ value of 1.7 nM. ALK-IN-24 also inhibits insulin receptor kinase with an IC₅₀ value of 6 nM. ALK-IN-24 suppresses the proliferation of lung adenocarcinoma cells. ALK-IN-24 inhibits ALK-driven tumor growth in xenograft mouse models. ALK-IN-24 can be used in research related to non-small cell lung cancer .

HY-181250

SHP2-IN-46	SHP2	Cancer
SHP2-IN-46 is an orally active SHP2 inhibitor (IC₅₀ = 11.76 μM). SHP2-IN-46 inhibits SHP2 enzymatic activity and mediates anti-tumor activity. SHP2-IN-46 suppresses cell proliferation in various cancer cells. SHP2-IN-46 can be used in research related to lung adenocarcinoma, pancreatic cancer and hepatoblastoma .

HY-101145

CK37	Choline Kinase p38 MAPK PI3K Akt Arp2/3 Complex PERK	Cancer
CK37 is a competitive choline kinase-α inhibitor. CK37 inhibits purified recombinant human choline kinase-α activity. CK37 suppresses MAPK and PI3K/AKT signaling, disrupts actin cytoskeletal organization. CK37 diminishs activating phosphorylations of ERK. CK37 exhibits anticancer activity against cervical cancer, melanoma, Lewis lung carcinoma, lung adenocarcinoma, breast cancer, and leukemia .

HY-164346

Amine-PEG8-Val-Cit-PAB-MMAE	Microtubule/Tubulin Drug-Linker Conjugates for ADC	Cancer
Amine-PEG8-Val-Cit-PAB-MMAE is a potent drug-linker conjugate for antibody-drug conjugates (ADCs).Amine-PEG8-Val-Cit-PAB-MMAE consists of the linker amine-PEG8-Vali-Cit-PAB and the payload MMAE (HY-15162), and can be used to synthesize ADCs. Amine-PEG8-Val-Cit-PAB-MMAE can be used for the research of gastric cancer, colon cancer, lung adenocarcinoma .

HY-142079

Br-C1-CONH-C5-CO-Val-Cit-PAB-MMAE	Drug Derivative	Cancer
Br-C1-CONH-C5-CO-Val-Cit-PAB-MMAE (compound 62) is a drug-linker conjugate that contains a monomethyl auristatin E (MMAE) drug moiety, which is linked to a bromoacetamide-containing extension unit via a valine-citrulline (Val-Cit) dipeptide and a self-immolative p-aminobenzyl (PAB) spacer. Br-C1-CONH-C5-CO-Val-Cit-PAB-MMAE is applicable to the research of breast cancer, anaplastic large cell lymphoma and lung adenocarcinoma .

HY-N16695

(2S,3S)-Pterosin S 14-O-glucoside	Others	Others
(2S,3S)-Pterosin S 14-O-glucoside is a sesquiterpene glycoside compound that can be isolated from the fern Pteris multifida. (2S,3S)-Pterosin S 14-O-glucoside showed no significant cytotoxicity against A549 (human lung adenocarcinoma), LOVO (colon adenocarcinoma), PANC-1 (human pancreatic cancer), and NCI-H446 (human small cell lung cancer) cell lines (IC₅₀ > 100 μM) .

Cat. No.	Product Name	Type

HY-P3371

Ifinatamab deruxtecan

DS-7300a; MABX-9001a; I-DXd

Fluorescent Dyes

Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects

HY-135146G

GSK-3484862

Fluorescent Dyes

GSK-3484862 GMP is GSK-3484862 (HY-135146) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. GSK-3484862 is a highly potent non-covalent inhibitor and demethylating agent of DNMT1. GSK-3484862 induces genome-wide DNA demethylation, including the regulatory elements of DNMT3B and the promoter region of TERT, and significantly inhibits cell viability, growth, proliferation and self-renewal. GSK-3484862 blocks the transformation of young AT2 cells, induces apoptosis, and generates transcriptomic features similar to those of senescent cells. GSK-3484862 is widely used in studies related to lung cancer, oral squamous cell carcinoma and lung adenocarcinoma .

Cat. No.	Product Name	Type

HY-401424

Cremophor EL-36

Polyoxyethylene(36) Castor Oil; PEG-36 Castor Oil

Biochemical Assay Reagents

Cremophor EL-36 is a non-ionic surfactant, mainly used as a solubilizing carrier for poorly soluble Paclitaxel (HY-B0015). For example, Cremophor EL-36 can enhance the intracellular influx of Etoposide (HY-13629) without affecting drug efflux, and can dose-dependently increase the accumulation of VP-16 in lung adenocarcinoma cells (such as PC-14 and A549), significantly enhancing its cytotoxic effect .

HY-42121

4-Bromo-2-fluoro-1-iodobenzene 4-Bromo-2-fluoroiodobenzene	Biochemical Assay Reagents
4-Bromo-2-fluoro-1-iodobenzene is an intermediate. 4-Bromo-2-fluoro-1-iodobenzene can be used in the synthesis of Example 33. 4-Bromo-2-fluoro-1-iodobenzene can be used in lung adenocarcinoma research .

HY-135146G

GSK-3484862

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P10010

DB21, Galectin-1 Antagonist	Galectin	Cancer
DB21, Galectin-1 Antagonist is a dibenzofuran conjugated peptidomimetic that acts as an allosteric inhibitor of galectin-1 (GAL1)binding to cell surface glycans. DB21, Galectin-1 Antagonis increases inhibition of angiogenesis and tumour growth in melanoma, lung adenocarcinoma and ovarian cancer models .

HY-P11280A

PRAME peptide (425-433) acetate	Melanocortin Receptor	Cancer
PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung* cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma .

Cat. No.	Product Name

HY-K6102

*Human Lung Adenocarcinoma* Organoid Kit**
MCE Human Lung Adenocarcinoma Organoid Kit contains Lung Adenocarcinoma Organoid Basal Medium A, Lung Adenocarcinoma Organoid Supplement B (50×), Lung Adenocarcinoma Organoid Supplement C (250×). This product can be used to efficiently construct human lung adenocarcinoma organoid.

Cat. No.	Product Name	Target	Research Area	Image

HY-P3371

Ifinatamab deruxtecan DS-7300a; MABX-9001a; I-DXd	Antibody-Drug Conjugates (ADCs) Topoisomerase Apoptosis	Cancer
Ifinatamab deruxtecan (DS-7300a) is a B7-H3-targeting Antibody-drug conjugate (ADC), which is composed of a humanized anti-B7-H3 monoclonal antibody, an enzymatically cleavable peptide-based linker, and Exatecan derivative (DXd) (HY-13631D). Ifinatamab deruxtecan is a DNA Topoisomerase I inhibitor. Ifinatamab deruxtecan induces Apoptosis. DS-7300a exerts potent antitumor activities against B7-H3-expressing tumors. against rhabdomyosarcoma, endometrial adenocarcinoma and lung adenocarcinoma. Ifinatamab deruxtecan does not exert direct immunomodulatory effects

HY-P99048

Sintilimab 1 Publications Verification IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a K_D value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P99048A

Sintilimab (Anti-PD-1) IBI308 (Anti-PD-1)	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a K_D value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P992341

D8P1C1	MMP	Cancer
D8P1C1 is a high-affinity ADAM17 inhibitor (with a K_d of 180 pM targeting ADAM17-ECD) that reduces the shedding and phosphorylation of EGFR ligands. D8P1C1 inhibits cancer cell proliferation in vitro and tumor growth in xenograft models. ⁸⁹Zr-DFO-D8P1C1 radioimmunological PET imaging shows its substantial accumulation in ovarian tumor xenografts, serving as a platform for generating bispecific T-cell engager derivatives. D8P1C1 can be applied to research on related diseases including triple-negative breast cancer, various types of ovarian cancer, lung adenocarcinoma, glioma, and colon cancer .

Cat. No.	Product Name		Classification

HY-146244

Agatolimod 1 Publications Verification ODN 2006; PF-3512676; CpG 7909; ODN 7909		CpG ODNs
Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a TLR9 agonist and immunomodulator with an EC₅₀ of 180 nM against human TLR9. Agatolimod activates and upregulates the expression of both TLR9 and TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-135146G

GSK-3484862	DNA Methyltransferase Apoptosis	Cancer
GSK-3484862 GMP is GSK-3484862 (HY-135146) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. GSK-3484862 is a highly potent non-covalent inhibitor and demethylating agent of DNMT1. GSK-3484862 induces genome-wide DNA demethylation, including the regulatory elements of DNMT3B and the promoter region of TERT, and significantly inhibits cell viability, growth, proliferation and self-renewal. GSK-3484862 blocks the transformation of young AT2 cells, induces apoptosis, and generates transcriptomic features similar to those of senescent cells. GSK-3484862 is widely used in studies related to lung cancer, oral squamous cell carcinoma and lung adenocarcinoma .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

lung+adenocarcinoma

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

NaturalProducts

Oligonucleotides

GMP Molecules

Natural
Products